Suppr超能文献

在接受 Janus 激酶抑制剂治疗的类风湿关节炎患者中,干扰素-γ 释放试验是否可靠地检测结核感染?

Are interferon-gamma release assays reliable to detect tuberculosis infection in patients with rheumatoid arthritis treated with Janus kinase inhibitors?

机构信息

Rheumatology Unit-Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy.

Saint Camillus International University of Health Science, Rome, Italy.

出版信息

PLoS One. 2022 Sep 28;17(9):e0275329. doi: 10.1371/journal.pone.0275329. eCollection 2022.

Abstract

BACKGROUND

Screening for latent tuberculosis infection is recommended in patients with rheumatoid arthritis (RA) starting Janus kinase inhibitors (Jaki). Interferon (IFN)-gamma release assays (IGRAs) are increasingly used for this purpose. Jaki tend to decrease the levels of IFNs, questioning the reliability of IGRAs during treatment with these drugs.

OBJECTIVES

To compare the performance of QuantiFERON-TB Gold Plus (QFT-P) and QFT Gold In-tube (QFT-GIT) in RA patients treated with Jaki.

METHODS

RA patients underwent QFT-P and QFT-GIT at baseline (T0), and after 3 (T3) and 12 months (T12) of treatment with Jaki. The agreement between the two tests was calculated. The agreement between IGRAs and tuberculin skin test (TST) or chest radiography at baseline was also determined. The variability of QTF-P results was longitudinally assessed.

RESULTS

Twenty-nine RA patients (F/M 23/6; median age/IQR 63/15.5 years; median disease duration/IQR 174/216 months) were enrolled. A perfect agreement was found between QFT-P and QFT-GIT at all times (κ = 1). At T0, no agreement was recorded between IGRAs and TST (κ = -0.08) and between TST and chest radiography (κ = -0.07), a low agreement was found between QFT-P and chest radiography (κ = 0.17). A variation of 33.3% in the results of QFT-P was recorded at T3 vs T0, of 29.4% at T12 vs T0, and of 11.8% at T12 vs T3. The median levels of IFN-γ produced by lymphocytes in response to the mitogen of QFT-P decreased after 3 months followed by an increase after 12 months (not significant). No change in the median number of circulating lymphocytes was documented. Glucocorticoids intake was associated with a higher probability of negative or indeterminate IGRA results at T0 (p<0.0001).

CONCLUSION

A response to IGRAs is detectable during treatment with Jaki. However, fluctuations in the results of IGRAs have been observed in the absence of correlation with clinical outcomes, thus challenging their interpretation.

摘要

背景

从 2023 年 1 月开始,推荐在使用 Janus 激酶抑制剂(Jaki)治疗的类风湿关节炎(RA)患者中进行潜伏性结核病感染筛查。干扰素(IFN)-γ释放测定(IGRAs)越来越多地用于此目的。Jaki 往往会降低 IFNs 的水平,这使得在使用这些药物治疗期间,IGRAs 的可靠性受到质疑。

目的

比较 QuantiFERON-TB Gold Plus(QFT-P)和 QFT Gold In-tube(QFT-GIT)在接受 Jaki 治疗的 RA 患者中的表现。

方法

RA 患者在基线(T0)、接受 Jaki 治疗 3 个月(T3)和 12 个月(T12)时进行 QFT-P 和 QFT-GIT。计算两种检测方法之间的一致性。还确定了基线时 IGRAs 与结核菌素皮肤试验(TST)或胸部 X 线之间的一致性。纵向评估 QTF-P 结果的变异性。

结果

共纳入 29 例 RA 患者(F/M 23/6;中位年龄/四分位数间距 63/15.5 岁;中位疾病持续时间/四分位数间距 174/216 个月)。QFT-P 和 QFT-GIT 在所有时间点均具有完美的一致性(κ=1)。在 T0 时,IGRAs 与 TST(κ=-0.08)和 TST 与胸部 X 线(κ=-0.07)之间没有一致性,QFT-P 与胸部 X 线之间的一致性较低(κ=0.17)。QFT-P 的结果在 T3 与 T0 时变化了 33.3%,在 T12 与 T0 时变化了 29.4%,在 T12 与 T3 时变化了 11.8%。在 3 个月后,淋巴细胞对 QFT-P 刺激物产生 IFN-γ的中位水平下降,随后在 12 个月后升高(无统计学意义)。未记录到循环淋巴细胞中位数的变化。糖皮质激素的摄入与 T0 时 IGRA 结果阴性或不确定的可能性更高相关(p<0.0001)。

结论

在接受 Jaki 治疗期间可以检测到对 IGRAs 的反应。然而,在没有与临床结果相关的情况下,观察到 IGRAs 结果的波动,这使得对其解释具有挑战性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b755/9518845/400ba19dd9fe/pone.0275329.g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验